Form 4: Fulcrum Therapeutics Executive Sells Shares to Cover Tax Obligations

Gregory Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics, sold 236 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On May 7, 2024, Gregory Tourangeau, the Principal Accounting Officer of Fulcrum Therapeutics, sold 236 shares of the company's common stock.
• The sale was executed at a price of $7.76 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Tourangeau directly owns 11,571 shares of Fulcrum Therapeutics.
• The sale was not a discretionary trade but an automatic 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (selling shares to cover taxes) and doesn't indicate any significant positive or negative sentiment.

Future Outlook

There are no forward-looking statements in this document.

Industry Context

Form 4 filings are routine and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The sale of shares by an officer could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates